World's Best Scientists 2026 revealed!
Kathleen I. Pritchard

Kathleen I. Pritchard

Award Badge
Best Female Scientists
2025
Award Badge
Medicine
Canada
2023

D-Index & Metrics

Best Female Scientists

D-Index
117
Citations
89100
World Ranking
625
National Ranking
18

Medicine

D-Index
120
Citations
93112
World Ranking
3654
National Ranking
149

Kathleen I. Pritchard publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Kathleen I. Pritchard sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 649 publications — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Kathleen I. Pritchard D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Kathleen I. Pritchard sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 120 D-Index — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award
  • 2023 - Research.com Medicine in Canada Leader Award

Overview

Kathleen I. Pritchard is affiliated with the University of Toronto in Canada and has a research focus predominantly in Medicine and Biochemistry, Genetics and Molecular Biology. Their work encompasses several specialized subfields including Oncology, Cancer Research, Genetics, Molecular Biology, and Pulmonary and Respiratory Medicine.

The main topics of Kathleen I. Pritchard's research involve Breast Cancer Treatment Studies, Estrogen and related hormone effects, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Cancer-related cognitive impairment studies, Bone health and treatments, and Advanced Breast Cancer Therapies.

Among the frequently published venues where they have contributed are Cancer Research, UNC Libraries, The Lancet, Journal of Clinical Oncology, and npj Breast Cancer.

Frequent collaborators in their research work include Lois E. Shepherd, Martine Piccart, Evandro de Azambuja, Mark N. Levine, and Dongsheng Tu.

Selected recent papers authored or co-authored by Kathleen I. Pritchard include:

  • Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials, 2021, The Lancet Oncology
  • Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100,800 women from 86 randomised trials, 2023, The Lancet
  • Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies, 2022, Nature Communications
  • Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx, 2020, Journal of Clinical Oncology
  • The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer, 2020, npj Breast Cancer

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

    Rebecca Dent;Maureen Trudeau;Kathleen I. Pritchard;Wedad M. Hanna

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

    C Focan;SM Steinberg;M Blichert-Toft;JF Forbes

  • Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

    José Baselga;Mario Campone;Martine Piccart;Howard A. Burris

  • A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

    Paul E. Goss;James N. Ingle;Silvana Martino;Nicholas J. Robert

  • Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

    R Peto;C Davies;J Godwin

  • Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

    Joseph A. Sparano;Robert J. Gray;Della F. Makower;Kathleen I. Pritchard

  • Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

    Kathy S Albain;William E Barlow;Steven Shak;Gabriel N Hortobagyi

  • American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

    Eric P. Winer;Clifford Hudis;Harold J. Burstein;Antonio C. Wolff

  • Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

    J. A. Sparano;R. J. Gray;D. F. Makower;K. I. Pritchard

  • 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

    Hongchao Pan;Richard Gray;Jeremy Braybrooke;Christina Davies

  • Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

    Paul E. Goss;James N. Ingle;Silvana Martino;Nicholas J. Robert

  • Regional Nodal Irradiation in Early-Stage Breast Cancer

    Timothy J. Whelan;Ivo A. Olivotto;Wendy R. Parulekar;Ida Ackerman

  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant

  • Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study

    Pamela J. Goodwin;Marguerite Ennis;Kathleen I. Pritchard;Maureen E. Trudeau

  • Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer.

    Charles Catzavelos;Nandita Bhattacharya;Yee C. Ung;James A. Wilson

  • Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

    M. N. Levine;V. H. Bramwell;K. I. Pritchard;B. D. Norris

  • Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System

    Clifford A. Hudis;William E. Barlow;Joseph P. Costantino;Robert J. Gray

  • Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

    J. Bergh;K. Pritchard;K. Albain;S. Anderson

Frequent Co-Authors

Mark Levine
Mark Levine McMaster University
Timothy J. Whelan
Timothy J. Whelan McMaster University
Paul E. Goss
Paul E. Goss Harvard University
Pamela J. Goodwin
Pamela J. Goodwin University of Toronto
Karen A. Gelmon
Karen A. Gelmon University of British Columbia
James N. Ingle
James N. Ingle Mayo Clinic
Martine Piccart
Martine Piccart Université Libre de Bruxelles
Michael Gnant
Michael Gnant Medical University of Vienna
José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Dongsheng Tu
Dongsheng Tu Queen's University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn’t always mean going to medical school. There are many alternative pathways and online programs that can help you advance in the healthcare sector while offering greater flexibility.

For those interested in healthcare leadership and administration, many cahme accredited mha online programs provide rigorous, accredited training focused on management within healthcare organizations.

Registered nurses looking to further their education might consider the best online rn to bsn programs without clinical requirements. These programs allow working professionals to earn a bachelor’s degree fully online, creating more opportunities for career growth.

For advanced practice nurses, moving up the educational ladder is now faster and more accessible with options like the shortest msn to dnp program, designed for those seeking the highest nursing credentials in record time.

Additionally, if you’re seeking the most direct and manageable route to a Doctor of Nursing Practice degree, exploring dnp programs can help you find a program that fits your schedule and goals.

With these online options, a rewarding healthcare career is more flexible and accessible than ever before.

Best Scientists Citing Kathleen I. Pritchard

Trending Scientists